NCT05377658View on ClinicalTrials.gov

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

AK104

10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.

DRUG

Albumin-Bound Paclitaxel

260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.

DRUG

Carboplatin

AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.

Trial Locations (1)

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV